GRAIL
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · California, United States · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
1525 O Brien Dr, Menlo Park, California,...Phone Number
(833) 464-7245Website
www.grail.comRevenue
$156.1 MillionStock Symbol
GRALIndustry
ZI Rank: 2
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
5
4
1
6
2
2
About GRAIL
GRAIL is a healthcare company dedicated to early cancer detection through innovative technologies, notably their Galleri test, which allows for multi-cancer early detection (MCED) by analyzing DNA in the bloodstream. The company aims to transform cancer screening and reduce mortality rates associated with cancer by utilizing advanced methylation analysis and machine-learning algorithms. Their intended clients include healthcare providers, oncologists, and individuals seeking proactive cancer screening solutions. GRAIL's mission focuses on changing the trajectory of cancer mortality by bringing together various stakeholders to adopt effective cancer detection technologies.Explore more
GRAIL Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is GRAIL your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
GRAIL, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if GRAIL had a recent Job posting/layoffs
Product Launch: Get notified when GRAIL launches new products
Website visits: Recent activity has been detected on your website
Check if GRAIL has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on GRAIL recently announced quarterly report
Funding: Get notified immidiatlly once GRAIL has new funding data
Congratulate Masked Content for being promoted to Masked Content at GRAIL
Check out if GRAIL is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined GRAIL as Masked Content
Find 3 more new buyers
Compare Similar Companies to GRAIL
Compare insights from companies similar to GRAIL, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
GRAIL is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
GRAIL is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about GRAIL.
GRAIL financials insights
Gather financial insights about GRAIL, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Series A
$100M
2017
Series B
$900M
2018
Series C
$300M
2019
Unspecified
$125M
2020
Series D
$390M
2025
Stock/Share Issuance
$325M
GRAIL Tech Stack
A closer look at the technologies used by GRAIL
See more technologies
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Promotion
Executive Move
Executive Moves, Promotion
Hiring Plans
GRAIL has more open roles in Operations than it has had at any time in the past 6 months.
Hiring Plans
Person-Based
Customer Service, Doctors / Physicians, Public Health
Project
Laboratory Operations, Medical Research, Clinical Operations
GRAIL News & Media
GRAIL, Inc. (GRAL) Shareholder/Analyst Call Transcript
GRAIL, Inc. (GRAL) Shareholder/Analyst Call May 31, 2026 7:00 PM EDTCompany ParticipantsRobert Ragusa - AdvisorJoshua Ofman - CEO, President &...GRAIL’s Galleri Test Cuts Stage 4 Cancer Diagnoses in Study Despite Missed Endpoint
GRAIL (NASDAQ:GRAL) said new data presented at the American Society of Clinical Oncology annual meeting showed its Galleri multi-cancer early detection blood test can identify more cancers through screening and reduce stage 4 diagnoses, though the company confirmed that a primary endpoint in its larGRAIL Presents PATHFINDER 2 Results of More Than 35,000 Participants Showing the Galleri® Test Substantially Increased Cancer Detection With Robust Performance and Favorable Safety at 2026 ASCO Annual Meeting
The Galleri Multi-Cancer Early Detection (MCED) Test Increased Cancer Detection 6.5 Fold When Added to Recommended Screenings for Breast, Colorectal, Cervical and Lung Cancer 71% of the New Cancers Detected by the Galleri Test Were in Stages I-III MENLO PARK, Calif., May 31, 2026...GRAIL Reports Full Results From NHS-Galleri Trial Demonstrating Substantial Reduction in Stage IV Cancer Diagnoses at 2026 ASCO Annual Meeting
No Reduction Observed in Combined Primary Endpoint of Stage III/IV Cancers in Aggregate; However, Decreases Observed Beyond the Prevalent Screening Round Annual Galleri® Blood Test Reduced Stage IV Diagnoses of 12 Prespecified Cancers by 22% and 26% in the Second and Third Screening...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding GRAIL
Sign Up For FreeTo access detailed company insights
GRAIL is a healthcare company dedicated to early cancer detection through innovative technologies, notably their Galleri test, which allows for multi-cancer early detection (MCED) by analyzing DNA in the bloodstream. The company aims to transform cancer screening and reduce mortality rates associated with cancer by utilizing advanced methylation an... Read More
